Answers are grounded in this paper and cite their sources.
BACKGROUND: Severe acute pancreatitis (SAP) is associated with increased thrombotic risk. Systemic release of pancreatic proteases in SAP may alter susceptibility to endogenous fibrinolysis, but this remains unexplored. Pancreatic carboxypeptidase B1 (CPB1) is a protease activated by trypsin that shares cleavage specificity with thrombin-activatable fibrinolysis inhibitor, which cleaves C-terminal lysine residues off fibrin, impairing co-localization of tissue plasminogen activator (tPA) and plasminogen and rendering clots resistant to fibrinolysis. We hypothesized that circulating CPB1 would be elevated in SAP patients and contribute to fibrinolytic resistance. METHODS: Plasma and clinical data were prospectively collected from SAP patients (n=15), matched critically ill controls without pancreatitis (n=13), and healthy controls (n=4) with IRB approval and informed consent. CPB1 levels were measured through ELISA. Clot lysis assays assessed fibrinolysis in response to tPA. Healthy control plasma was tested with and without porcine pancreas CPB1 to assess the effect of CPB1 on fibrinolysis. Transition midpoints (T M ’s) were defined as the time to 50% clot lysis. Clinical data were analyzed using Mann-Whitney U and Fisher exact tests. Assay results were analyzed using Kruskall-Wallis test. Significance was set at P <0.05. RESULTS: Demographics were similar between groups. SAP patients had markedly elevated CPB1 levels (154.0 [58.4–388.0] ng/mL) compared with sick (7.0 [4.1–15.6] ng/mL, P <0.0001) and healthy controls (4.0 [2.1–4.4], P <0.001). Healthy control plasma supplemented with porcine pancreas CPB1 demonstrated complete disruption of fibrinolysis compared with healthy plasma without CPB1. SAP patients had the highest resistance to tPA-induced fibrinolysis, with significantly higher baseline TMs than critically ill controls (42.0 [21.7–126.6] vs. 22.8 [18.3–33.7], P =0.04). CONCLUSIONS: Patients with SAP have uniquely elevated circulating levels of CPB1, which may contribute to thromboembolism in SAP through fibrinolytic resistance. Further investigation into targeted CPB1 inhibition as a potential therapeutic strategy in SAP is warranted to potentially reduce development of organ failure and mortality. LEVEL OF EVIDENCE: N/A (Basic Science).
No takes yet. Share an insight, caveat, or question.
Barmettler et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: